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Abstract 
Pleural effusions are rare in the newborn. Still, being familiar with this condition is relevant 
given its association with a wide range of disorders. Only two large series of cases on this 
matter have been published, with no solid conclusions established. The aim of this study is to 
determine the etiology, management and prognosis of pleural effusions in a population of high-
risk neonates. 
The authors performed a retrospective study in the Neonatal Intensive Care Unit of Hospital de 
São João, Porto, between 1997 and 2014, of all newborns with the diagnosis of pleural effusion, 
chylothorax, hemothorax, empyema, fetal hydrops or leakage of total parenteral nutrition. 
Eighty-two newborns were included, 48 males and 34 females. Pleural effusions were 
congenital in 19 (23.2%) newborns and acquired in 63 (76.8%). Fetal hydrops was the most 
frequent cause (15 cases, 78.9%) of congenital effusions while postoperative after intrathoracic 
surgery was the most common cause (39 cases, 61.9%) of acquired effusions, followed by 
leakage of total parenteral nutrition (13 cases, 20.6%). Chylothorax was the most common type 
of effusion (41.5% of cases). Pleural effusions after intrathoracic surgery were mainly (64.1%) 
chylothoraces. Regarding use of octreotide for treatment of chylous effusions, the comparative 
analysis showed no statistical differences between the group of alive newborns who received 
octreotide and the group who did not. Twenty-seven (32.9%) newborns died; the causes of 
death were related to underlying diseases and not to the pleural effusion. Clinical outcome is 
generally good, except in hydropic neonates. Blood albumin level appears to be predictive of 
prognosis and further investigation on its clinical significance should be encouraged. 
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Introduction 
The pleural space exists between the parietal pleura of the chest wall and the visceral pleura of 
the lung. Both pleural surfaces filter fluid into the pleural space and the lymphatics are 
responsible for most of the fluid reabsorption [1]. Pleural effusion, defined as fluid 
accumulation in the pleural space, can occur if the rate of filtration increases, or if the rate of 
lymphatic clearance decreases, or if both of these mechanisms are present [2]. 
Pleural effusions are rare in the neonate [3]. Nevertheless, being familiar with this condition is 
relevant because of its generally favorable prognosis [4]. Effusions may be diagnosed 
antenatally or they can appear at any time during the neonatal period. They may be 
asymptomatic or present with respiratory distress [2]. 
Several causes have been described in the literature, including congenital and acquired 
chylothoraces, fetal hydrops, and parapneumonic effusions [4]. There are also reports of 
hemothorax and leakage of parenteral nutrition, which are usually iatrogenic complications [3, 
5]. Still, information on the relative frequencies of these disorders as causes of pleural effusions 
is sparse. 
Treatment options and clinical outcomes are also poorly described. Guidelines for management 
of pediatric chylothorax have been proposed [6, 7] but only one publication presents specific 
guidelines for the neonatal period [8]. Moreover, new therapeutic approaches have been 
developed and no prospective or randomized trials have yet been performed [9]. 
There are only two recent publications reporting large series of pleural effusions in the fetus and 
newborn and no solid conclusions have been established so far [3, 10]. Therefore, the aim of 
this study is to investigate etiology, clinical management and prognosis of neonatal pleural 
effusions in a tertiary neonatal intensive care unit (NICU). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Material and methods 
All newborns admitted to the NICU of Hospital de São João, Porto, between 1997 and 2014, 
with the discharge diagnosis of pleural effusion, chylothorax, hemothorax, empyema, fetal 
hydrops or leakage of total parenteral nutrition (TPN) were included. Our NICU is a level III 
unit and a reference center for cardiothoracic surgery. All the data were obtained by a 
retrospective search from the hospital computer database and medical records.  
Demographic data and information regarding pregnancy and delivery were recorded. Pleural 
effusion characteristics were also collected: congenital or acquired, laterality, volume, clinical 
presentation, other associated effusions, prenatal diagnosis, gestational age at diagnosis, 
duration of the effusion and biochemical, cytological and bacteriological analysis of the fluid. In 
addition, data regarding treatment and neonatal morbidity and mortality were collected. 
Pleural effusions were diagnosed by chest radiography (standard supine anteroposterior 
projection) and/or chest ultrasound and classified as: small – if they were apparent in not more 
than a quarter lung field; moderate – if apparent in a quarter to half lung field; large – if 
apparent in more than half lung field; massive – if apparent around the entire lung with 
mediastinal shift [3]. Type of effusion was assessed based on biochemical and cytological 
analysis of the fluid. Etiology of the effusion was established according to the clinical setting 
and medical history. 
Chylothorax was defined according to the criteria proposed by Buttiker et al: an absolute white 
cell count >1000 cells/µL with a lymphocyte fraction >80% and triglyceride levels >110 mg/dL 
in pleural fluid (provided there was minimal fat enteral intake) [6] and treated according to the 
published guidelines [8]. Transudates were effusions with a total protein level <3.0 g/dl or a 
pleural/serum protein ratio <0.5, and a total leukocyte count <1000/mm
3
 with predominance of 
mononuclear cells. Exudate was defined by the presence of at least one of the following: protein 
level >3.0 g/dl with pleural/serum protein ratio >0.5; pleural fluid lactic dehydrogenase (LDH) 
values >200 IU/L; or a pleural-to-serum LDH ratio >0.6 [11]. Empyema was defined as an 
exudative effusion presenting with purulent appearance and a total leukocyte count >5000/mm
3
 
with predominance of polymorphonuclear cells (PMNs). Hemothorax was diagnosed based on 
the presence of blood in the pleural space [11]. Leakage of TPN was considered in neonates 
with a central venous catheter that presented a pleural fluid with a low leukocyte count and high 
concentrations of both glucose and potassium [5]. 
Fetal hydrops was defined as an excessive fluid accumulation within the fetal extravascular 
compartments and body cavities, characterized by generalized skin thickness of >5 mm, 
placental enlargement, pericardial or pleural effusion, or ascites [12]. 
Gestational age was assessed by post-menstrual age, ultrasound examination [13] or the New 
Ballard Score (in the absence of obstetrical indexes) [14]. Small for gestational age was defined 
as a birth weight below 3rd percentile of Fenton’s fetal growth charts [15]. 
Hyaline membrane disease was defined based on the european guidelines [16]. The diagnosis of 
bronchopulmonary dysplasia was made according to the NIH Consensus definition [17]. 
Hemodynamically significant patent ductus arteriosus was diagnosed according to SIBEN 
consensus [18]. The diagnosis and staging of necrotizing enterocolitis was established based on 
Bell criteria [19]. Intraventricular hemorrhage was classified according to Papile [20] (before 
2010) and Volpe [21] (after 2010). Cystic periventicular leukomalacia was classified according 
to de Vries and Rennie [22]. Staging of retinopathy of prematurity was done according to the 
international classification [23]. Proven neonatal sepsis was defined as any systemic infection 
documented by a positive blood culture. Pneumonia was diagnosed based on clinical, 
radiological and bacteriological parameters. Hypoalbuminemia was defined by a blood albumin 
level < 35 g/L [2]. 
The statistical analysis was performed using SPSS for Windows, version 20. Continuous 
variables were characterized by mean (± standard deviation) or median (medium-maximum) if 
they had symmetric or asymmetric distribution respectively and categorical variables by 
absolute and relative frequencies. To compare continuous variables non-parametric tests (Mann 
Whitney-U test or Kruskal Wallis test) were used if they had two or more than two categories, 
and Chi-Squared or Fisher’s exact test to compare categorical variables, the latter for expected 
values less than 5. A multivariate analysis by logistic regression was performed to evaluate 
predictive factors for death. A p value less than 0.05 was considered statistically significant. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
During the 18 years of the study period, about 7200 newborns were admitted to the NICU and 
82 neonates with pleural effusion were retrieved and studied. The incidence of effusions in our 
series was 110 per 10000 neonates. Demographic and clinical data are summarized in Table 1. 
Pleural effusions were congenital in 19 (23.2%) neonates and acquired in 63 (76.8%). The 
etiologies of each category are described in Table 2.  
We observed 15 cases of congenital pleural effusion with fetal hydrops. Five (33.3%) of them 
were chylothoraces, nine (60%) were transudates and one (6.7%) was of unknown type. Out of 
the nine transudates, five (55.6%) were caused by fetal arrhythmia, one (11.1%) by twin-to-twin 
transfusion syndrome, one (11.1%) by hemochromatosis, one (11.1%) by congenital nephrotic 
syndrome and one (11.1%) was idiopathic. 
Regarding acquired effusions, 39 (61.9%) were iatrogenic after intrathoracic surgery. The 
association was found for surgical interventions on three types of major congenital 
malformations: congenital heart disease (CHD), diaphragmatic hernia and esophageal atresia. 
These postoperative effusions were chylothoraces in 25 (64.1%) cases. 
Extravasation of TPN was identified in 13 newborns (20,6% of the acquired effusions). They 
were unilateral in eight (61.5%) cases and of moderate volume in five (38.5%). Four of them 
had spontaneous resolution of the effusion after catheter removal, with no need for further 
intervention. The median duration of effusions in this group was 2 days (range, 1-6 days). Two 
of the newborns died. 
Three newborns developed parapneumonic effusions; fluid analysis was consistent with 
empyema in all of them.  
Of the three cases of hemothorax, one was congenital and occurred in a newborn with a 
paravertebral neuroblastoma associated with disseminated intravascular coagulation. The other 
two were acquired; one in a newborn performing anticoagulation therapy for extracorporeal 
membrane oxygenation (ECMO) and the other as a complication of cardiac catheterization with 
pulmonary hemorrhage. In this group the median duration of the effusions was 2 days (range, 1-
14 days) and all of them died. 
Chylothorax was the diagnosed type of effusion in 34 (41.5%) neonates. Other types were: 23 
(28.0%) transudates, seven (8.5%) exudates, 13 (15.9%) cases of fluid consistent with TPN, 
three (3.7%) cases of fluid consistent with blood (hemothorax) and two (2.4%) unknown. Table 
3 shows pleural effusion characteristics and demographic/clinical data of the three major types. 
Chylous effusions are described in more detail in Table 4. Twelve neonates with chylothorax 
were treated with octreotide; five of them died. The comparative analysis of clinical outcomes 
in both congenital and acquired chylous effusions showed no statistical differences between the 
group of alive newborns who received octreotide and the group who did not. 
In this series, 27 (32.9%) newborns died (nine in the group of congenital effusions and 18 in the 
group of acquired effusions). The causes of death were related to the underlying disease and not 
to the pleural effusion. The analysis of predictor factors for death showed that higher blood 
levels of albumin are protective (OR 0.912; 95% CI 0.85-0.98); a blood albumin level ≤ 12.1 
g/L had a sensitivity of 81.5% for mortality. 
  
 
 
 
 
 
 
 
 
 
Discussion 
The 82 cases of neonatal pleural effusions identified in our study are representative of 18 years 
of retrospective investigation, which is longer than any other series described. Our estimated 
effusions’ incidence, 110 per 10000 admissions, is according to the literature (from 5.5 to 220 
per 10000 admissions) [3, 24]. In our study there were no significant differences between 
gender, although pleural effusions occurred more commonly in males as described in previous 
reports [2]. 
 
 
Etiology and management 
As described in Table 2, acquired effusions were more common than congenital ones, 
comprising about three-quarter of the cases. Regarding congenital effusions, fetal hydrops was 
the most frequent etiology and transudate was the most frequent type. Concerning acquired 
effusions, postoperative after intrathoracic surgery was the most common etiology and 
chylothorax was the most common type.  
Comparing the three major types of effusion (Table 3), the preponderance of acquired effusions 
is observed in all of them. Apgar scores appeared to be lower immediately after birth, with 
slight recovery at 5
th
 minute, and none of the exudates had low scores; this is probably related to 
the morbidity caused by congenital effusions at birth. Associated effusions in other cavities, 
namely ascites and subcutaneous edema, were especially found in transudates, probably 
dependent on the cases of fetal hydrops. About associated malformations, transudates were 
particularly found in diaphragmatic hernias, possibly because of physiological disturbances of 
fluid regulation following surgical repair of the hernia sac. On the other hand, chylothoraces 
were more commonly associated to CHD, probably because of postoperative effusions. In fact, 
postoperative effusions were mainly chylous. There were also differences on treatment 
modalities between types: although thoracocentesis was equally performed, chest tube drainage 
was particularly used in chylothoraces while diuretic therapy was a frequent option for 
transudates. As expected, octreotide, medium-chain triglycerides (MCT) and thoracic duct 
ligation were only used in chylothoraces. 
 
 
Chylous effusions 
Chylothorax is a rare cause of respiratory distress in the newborn and the most common form of 
pleural effusion in the neonatal period [25]. In fact, chylothorax was the most common type of 
effusion (41.5%) in this study. It is defined by the accumulation of chyle in the pleural space [6] 
and some authors distinguish three subtypes according to its cause: congenital, traumatic and 
nontraumatic [4, 6, 25]. 
 
 
Congenital chylothorax 
The etiology of congenital chylothorax is not well understood, but it is thought to occur 
secondary to trauma to the thoracic duct during delivery or a congenital malformation of the 
lymphatic vessels [26].  
All congenital chylothoraces in our study were bilateral, with lower apgar scores at 5
th
 minute 
and occasional need for immediate thoracocentesis in the delivery room, confirming that these 
were high-risk and unstable neonates with associated morbidities, namely fetal hydrops. In fact, 
in our series congenital chylothorax was associated with hydrops in 71.4% of the cases, as 
already reported in other publications [3]. Congenital chylothorax has also been associated with 
genetic diseases such as Noonan, Down’s and Turner syndromes, and primary congenital 
pulmonary lymphangiectasis [27] but this association was not found in our series. 
The management of this effusion starts from the antenatal period [26]. In our series, 42.9% of 
these infants had some in utero intervention (two pleuro-amniotic shuntings and one pleural 
drainage during amniocentesis); the therapeutic benefit of antenatal drainage relates to 
resolution of fetal hydrops and prevention of pulmonary hypoplasia and intrauterine fetal death 
[27]. In our study, thoracocentesis was the preferred strategy in postnatal management. 
Octreotide was used in two cases and both of them died because of other morbidities. The 
published reports about octreotide efficacy in congenital effusions have showed mixed success: 
Shah et al observed good results [9] while Horvers et al found no clear and consistent effect 
[28]. Both series highlight the need of a randomized controlled trial for further investigation. 
 
 
Acquired chylothorax 
Traumatic chylothorax in the neonate is in most cases iatrogenic after intra-thoracic surgery 
[25]. It may also occur following the use of ECMO catheters or insertion of chest tubes too far 
for the treatment of pneumothorax [2]. In our study, the majority of acquired chylothoraces were 
indeed postoperative (92.6%); we also report one case of complication after pneumothorax 
drainage (3.7%). The non-traumatic form is extremely rare in the neonatal period and it is 
caused by an obstruction of the thoracic duct by intra-thoracic tumors, inflammatory diseases or 
mediastinal lymphangiomatosis [25]. In our series, we report one case of compression by a 
cervical teratoma (3.7%). 
In this study, acquired chylothoraces were mainly unilateral, left-sided and of moderate volume. 
Postoperative effusions were particularly relevant, as reported in other series [3, 10]. This 
association was stronger for CHD interventions once 52.0% of the postoperative chylothoraces 
occurred following cardiac surgery, as supported by published data [29]. Chylothoraces after 
surgery on diaphragmatic hernias and esophageal atresias have been described [30, 31] but in 
this study they were less common (24.0% each). 
Regarding treatment, these patients had increasing therapeutic needs and required a longer 
NICU stay. Two neonates required surgical management with thoracic duct ligation due to 
failure of medical therapy; no complications were registered. 
Octreotide has been used in postoperative chylothoraces with promising results [32]. Although a 
published series presented poor outcomes [30] and despite the significant heterogeneity of case 
reports, a recent review concluded that octreotide is relatively safe, and may reduce 
complications in these patients; a randomized trial is again proposed [32]. In this series, 
octreotide was used in 10 patients and no significant effects were observed. 
 
 
Fetal hydrops 
In this study, the majority of congenital pleural effusions (78.9%) occurred as nonimmune fetal 
hydrops (NIFH). In fact, NIFH is an important documented cause of congenital pleural effusion 
[3]. In our study, cardiovascular disorders and lymph vessel dysplasia (congenital chylothorax) 
were the two major causes of NIFH and they were equally relevant, each one accounting for one 
third of the hydrops cases. These etiologies are consistent with previous reports, although their 
relative frequency varies in the literature. Bellini et al described cardiovascular diseases as the 
predominant cause (21.7%) [12], while Takci et al reported lymphatic dysplasia as the most 
common diagnosis (23.5%) [33]. 
Despite the advances in diagnosis and management, NIHF still presents a high mortality rate 
(40-50%) [34]. In our series, the mortality rate in hydropic neonates was 53.3%. Huang et al 
found that hydrops resulting from lymphatic dysplasias had a more favorable outcome [34]; that 
association was not found in our sample. 
 
 
Leakage of total parenteral nutrition 
Extravasation of parenteral fluid as a complication of central venous catheter use is rare [10]; 
still, it should be considered in any neonate who develops a pleural effusion while receiving a 
central venous infusion. An important differential in these cases is chylothorax due to thoracic 
duct injury during central line insertion [35]; biochemical analysis of the fluid allows the 
diagnostic distinction [5]. 
In our study, leakage of TPN constituted a relevant etiology, being the second most common 
cause of acquired effusions. All these neonates had percutaneously inserted central venous 
catheters (PICC). TPN effusions were mostly unilateral (61.5%), which is consistent with 
previous findings [3]. The resolution of the effusion was fastest in these cases because there was 
prompt removal of the triggering agent (catheter) and discontinuation of TPN infusion. 
 
 
Pneumonia 
Pneumonias can complicate with the spreading of bacterial infection within the thoracic cavity, 
resulting in pleural effusions, usually empyemas. Staphylococcus aureus, Streptococcus 
pneumoniae and Streptococcus pyogenes are the most common causes [11]; other agents, like 
Bacteroides fragilis and Acinetobacter calcoaceticus, have also been reported [3, 24]. Out of the 
three empyemas diagnosed in our series, one case was secondary to meconium aspiration 
syndrome and the other two were caused by Acinetobacter and Enterobacter aerogenes. 
 
 
Hemothorax 
Hemothorax most commonly occurs after chest trauma; it is also an occasional manifestation of 
blood dyscrasias, intrathoracic neoplasms, thrombolytic therapy, and iatrogenic erosion of 
vessels by surgical procedures [11]. The three cases of hemothorax found in our series had a 
fatal outcome. Still, no prognostic conclusions can be assessed given the limited number of 
cases. 
 
 
 
 
Prognosis 
The mortality rate was relevant (32.9%) but none of the deaths was directly related to the 
effusion. There are reports of patients dying because of pulmonary hypoplasia related to 
congenital effusions [3] but this association was not found in our sample. In this study, the 
major causes of mortality were multiorganic failure, sepsis and extensive hemorrhagic 
disorders. 
From all the variables studied, only blood albumin levels were predictive of prognosis: lower 
levels were associated to death in both chylous and non-chylous effusions. According to this, 
we speculated that hypoalbuminemia may reflect worst clinical condition of the patient. 
Although hypoalbuminemia was already described as a common complication of congenital 
chylothoraces [27], no information on its prognostic significance in neonatal effusions is 
reported in the literature. Further investigation on this matter should be encouraged in order to 
assess if blood albumin levels could become an analytic marker of prognosis in these patients. 
 
 
 
 
 
 
 
Conclusion 
Pleural effusions are rare in the neonate and can be associated with several clinical conditions. 
Acquired effusions are more common than the congenital forms, which present as fetal hydrops 
in most of the cases. Traumatic chylothorax after intrathoracic surgery is the major cause of 
acquired effusions. Prompt diagnosis and adequate management are crucial. Blood albumin 
levels appear to be predictive of prognosis but further investigation on this matter should be 
encouraged. Clinical outcome is generally good, except in hydropic neonates. 
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Tables 
        Table 1 – Demographic and clinical data of the newborns with pleural effusion (n=82) 
Gender, n (%) 
   Male 
   Female 
 
48 (58.5) 
34 (41.5) 
Birth weight (grams), mean (±SD) 2476 (±941) 
Small for gestational age, n (%) 9 (11.0) 
Gestational age (weeks), mean (±SD) 35 (±4.3) 
Surveillance during pregnancy, n (%) 81 (98.8) 
Parity, n (%) 
   Single 
   Multiple  
 
72 (87.8) 
10 (12.2) 
Prenatal period 
  Steroids use, n (%) 
    Full cycle 
  Polyhydramnios 
  Fetal hydrops 
 
27 (32.9) 
16 (59.3) 
16 (19.5) 
15 (18.3) 
Delivery, n (%) 
   Vaginal 
   C-section 
 
25 (30.5) 
57 (69.5) 
Apgar score, n (%) 
   1
st
 minute < 7 
   5
th
 minute < 7 
 
39 (48.1) 
21 (26.3) 
Resuscitation, n (%) 
   Endotracheal tube 
45 (61.6) 
42 (93.3) 
Associated congenital malformations, n (%) 53 (65.5) 
Chromosomopathy, n (%) 4 (8.0) 
Dysmorphic syndrome, n (%) 
a
 4 (5.0) 
NICU stay (days), median (min-max) 26 (0-167) 
Deceased, n (%) 
b
 
   Autopsy 
27 (32.9) 
19 (70.4) 
 NICU – Neonatal Intensive Care Unit 
a
 Down’s syndrome (2), DiGeorge syndrome (1), Klippel-Feil syndrome (1) 
b 
multiorganic failure (8), sepsis (7), extensive hemorrhagic disorders (6), congestive heart 
failure (2), pulmonary hypoplasia (2), fetal arrhythmia (1), alveolar capillary dysplasia (1) 
 
 
 
 
 
 
 
 
Table 2 – Etiologies and types of pleural effusions 
Etiology, n (%) 
Type, n (%) 
Chy Trans Exu TPN Hem Unk 
Congenital 
   Fetal hydrops 
   Isolated congenital chylothorax 
   Congestive heart failure 
   Coagulopathy and intrathoracic neoplasm 
Acquired 
   Postoperative (after intrathoracic surgery) 
       Congenital heart disease 
       Congenital diaphragmatic hernia 
       Esophageal atresia 
   Leakage of total parenteral nutrition 
   Pneumonia 
   Compression by intrathoracic tumor 
   Complication of pneumothorax drainage 
   Superior vena cava syndrome 
   Coagulopathy by thrombolytic therapy 
   Nephrotic syndrome 
   Congestive heart failure and hypoproteinemia 
   Congestive heart failure and nephrotic syndrome 
   Unknown 
19 (23.2) 
15 (78.9) 
2 (10.5) 
1 (5.3) 
1 (5.3) 
63 (76.8) 
39 (61.9) 
15 (38.5) 
16 (41.0) 
8 (20.5) 
13 (20.6) 
3 (4.7) 
1 (1.6) 
1 (1.6) 
1 (1.6) 
1 (1.6) 
1 (1.6) 
1 (1.6) 
1 (1.6) 
1 (1.6) 
7 (36.8) 
5 (71.4) 
2 (28.6) 
- 
- 
27 (42.9) 
25 (92.6) 
13 (52.0) 
6 (24.0) 
6 (24.0) 
- 
- 
1 (3.7) 
1 (3.7) 
- 
- 
- 
- 
- 
- 
10 (52.6) 
9 (90) 
- 
1 (10) 
- 
13 (20.6) 
9 (69.2) 
- 
9 (100) 
- 
- 
- 
- 
- 
- 
- 
1 (7.7) 
1 (7.7) 
1 (7.7) 
1 (7.7) 
0 
- 
- 
- 
- 
7 (11.1) 
4 (57.1) 
1 (25.0) 
1 (25.0) 
2 (50.0) 
- 
3 (42.9) 
- 
- 
- 
- 
- 
- 
- 
- 
0 
- 
- 
- 
- 
13 (20.6) 
- 
- 
- 
- 
13 (100) 
- 
- 
- 
- 
- 
- 
- 
- 
- 
1 (5.3) 
- 
- 
- 
1 (100) 
2 (3.2) 
1 (50) 
1 (100) 
- 
- 
- 
- 
- 
- 
- 
1 (50) 
- 
- 
- 
- 
1 (5.3) 
1 (100) 
- 
- 
- 
1 (1.6) 
- 
- 
- 
- 
- 
- 
- 
- 
1 (100) 
- 
- 
- 
- 
- 
Chy – chylothorax; Trans – transudate; Exu – exudate; TPN – Total parenteral nutrition; Hem – 
hemothorax; Unk – unknown 
 
 
 
 
 
 
 
 
 
 
Table 3 – Pleural effusion characteristics and demographic/clinical data according to type 
 Chylothorax 
(n=34) 
Transudate 
(n=23) 
Exudate 
(n=7) 
P 
Gender, n (%) 
   Male 
   Female 
 
24 (70.6) 
10 (29.4) 
 
15 (65.2) 
8 (34.8) 
 
5 (71.4) 
2 (28.6) 
 
0.925
*
 
Gestational age at birth (weeks), median (min-
max) 
37 (25-40) 37 (26-40) 38 (30-39) 0.840
§
 
Birth weight (grams), median (min-max) 2708 (705-4270) 3045 (535-3770) 2663 (1290-3142) 0.261
§
 
Small for gestational age, n (%) 4 (11.8) 2 (8.7) 0 0.859
*
 
Parity, n (%) 
   Single 
   Multiple 
 
30 (88.2) 
4 (11.8) 
 
22 (95.7) 
1 (4.3) 
 
6 (85.7) 
1 (14.3) 
 
0.561
*
 
Type, n (%) 
   Congenital 
   Acquired 
 
7 (20.6) 
27 (79.4) 
 
10 (43.5) 
13 (56.5) 
 
0 
7 (100) 
 
0.042
*
 
Prenatal diagnosis, n (%) 6 (17.6) 4 (17.4) 0 0.776
*
 
Gestational age at diagnosis (weeks), mean (±SD) 30 (23-35) 32 (30-37) - 0.195
§
 
Delivery, n (%) 
   Vaginal 
   C-section 
 
12 (35.3) 
22 (64.7) 
 
5 (21.7) 
18 (78.3) 
 
4 (57.1) 
3 (42.9) 
 
0.212
*
 
Apgar score, n (%) 
   1
st
 minute < 7 
   5
th
 minute < 7 
 
14 (41.2) 
8 (23.5) 
 
15 (65.2) 
9 (40.9) 
 
0 
0 
 
0.006
*
 
0.088
*
 
Endotracheal intubation at birth, n (%) 17 (56.7) 15 (71.4) 0 0.128
*
 
Laterality, n (%) 
   Unilateral 
       Right 
       Left 
   Bilateral 
 
18 (52.9) 
7 (38.9) 
11 (61.1) 
16 (47.1) 
 
11 (47.8) 
6 (54.5) 
5 (45.5) 
12 (52.2) 
 
6 (85.7) 
3 (50) 
3 (50) 
1 (14.3) 
 
0.228
*
 
0.664
*
 
 
0.228
*
 
Volume, n (%) 
   Small 
   Moderate 
   Large 
 
7 (20.6) 
21 (61.8) 
6 (17.6) 
 
12 (52.2) 
6 (26.1) 
5 (21.7) 
 
4 (57.1) 
3 (42.9) 
0 
 
0.032
*
 
Respiratory distress, n (%) 26 (76.5) 13 (56.5) 7 (100) 0.059
*
 
Other associated effusions, n (%) 
   Ascites 
   Pericardial 
   Subcutaneous edema 
10 (29.4) 
9 (26.5) 
4 (11.8) 
8 (23.5) 
14 (60.9) 
13 (56.5) 
7 (30.4) 
11 (47.8) 
2 (28.6) 
1 (14.3) 
1 (14.3) 
0 
0.058
*
 
0.029
*
 
0.164
*
 
0.028
*
 
Associated congenital malformation, n (%) 
   Heart disease 
   Diaphragmatic hernia 
   Esophageal atresia 
   Others 
 
13 (38.2) 
6 (17.6) 
6 (17.6) 
1 (2.9) 
 
2 (8.7) 
9 (39.1) 
0 
1 (4.3) 
 
3 (42.9) 
1 (14.3) 
2 (28.6) 
0 
 
0.009
*
 
Chromosomopathy, n (%) 3 (12) 0 0 0.423
*
 
Dysmorphic syndrome, n (%) 2 (6.3) 0 1 (14.3) 0.217
*
 
Neonatal morbidity, n (%) 
   Hyaline membrane disease 
   Brochopulmonary dysplasia 
   Patent ductus arteriosus 
       Surgical closure 
   Necrotizing enterocolitis ≥grade 2 
   Intraventricular hemorrhage ≥ grade 3 
   Leukomalacia periventricular 
 
7 (21.2) 
3 (8.8) 
14 (41.2) 
4 (28.6) 
1 (3) 
1 (33.3) 
3 (9.4) 
 
7 (31.8) 
4 (17.4) 
9 (39.1) 
0 
2 (8.7) 
1 (100) 
1 (4.5) 
 
1 (16.7) 
2 (28.6) 
2 (28.6) 
1 (100) 
0 
1 (50) 
0 
 
0.680
*
 
0.234
*
 
0.934
*
 
0.455
*
 
0.694
*
 
0.999
*
 
0.765
*
 
   Retinopathy of prematurity ≥ grade 2 
   Sepsis 
   Pneumonia 
2 (50) 
19 (55.9) 
3 (9.4) 
1 (100) 
9 (39.1) 
2 (9.1) 
0 
4 (57.1) 
3 (42.9) 
0.999
*
 
0.459
*
 
0.087
*
 
Previous thoracic surgery, n (%) 
   Day of diagnosis  after surgery, median (min-max) 
25 (73.5) 
6 (1-63) 
9 (39.1) 
4 (1-9) 
4 (57.1) 
3 (1-6) 
0.031
* 
0.189
§
 
Duration of pleural effusion (days), median (min-
max) 
 
11 (1-108) 
 
8 (2-32) 
 
15 (1-30) 
 
0.661
§
 
Treatment, n (%) 
   Spontaneous resolution 
   Thoracocentesis 
   Chest tube 
       Duration (days), median (min-max) 
   Octreotide 
   Medium-chain triglycerides 
   Albumin infusion 
   Diuretics 
   Thoracic duct ligation 
 
3 (8.8) 
10 (29.4) 
24 (70.6) 
10 (1-54) 
12 (35.3)  
16 (47.1) 
6 (17.6) 
14 (41.2) 
2 (5.9) 
 
4 (17.4) 
4 (17.4) 
8 (34.8) 
13 (2-32) 
0 
0 
8 (34.8) 
15 (65.2) 
0 
 
0 
2 (28.6) 
4 (57.1) 
8 (1-30) 
0 
0 
1 (14.3) 
1 (14.3) 
0 
 
0.503
*
 
0.586
*
 
0.026
*
 
0.774
§
 
0.001
*
 
<0.001
*
 
0.308
*
 
0.041
* 
0.602
*
 
Mechanical ventilation, n (%) 
   Mechanical ventilation (days), median (min-max) 
31 (91.2) 
19 (1-96) 
20 (87.0) 
11 (2-89) 
7 (100) 
16 (7-57) 
0.844
* 
0.206
§
 
Oxygen therapy, n (%) 
   Oxygen therapy (days), median (min-max) 
31 (91.2) 
17 (1-167) 
23 (100) 
13 (1-156) 
7 (100) 
16 (10-69) 
0.484
* 
0.241
§
 
Start of enteral feeding (days), median (min-max) 30 (14-106) 11 (8-49) 13 (13-13) 0.077
§
 
Parenteral feeding, n (%) 
   Parenteral feeding (days), median (min-max) 
29 (85.3) 
20 (1-119) 
21 (91.3) 
16 (2-88) 
7 (100) 
15 (12-63) 
0.616
* 
0.235
§
 
NICU stay (days), median (min-max) 38 (1-167) 21 (3-135) 41 (12-167) 0.064
§
 
Deceased, n (%) 11 (32.4) 8 (34.8) 3 (42.9) 0.930
*
 
*
 Fisher’s exact test, §Kruskal-Wallis test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4 – Characteristics and demographic/clinical data of chylous pleural effusions (n=34) 
 Congenital (n=7) Acquired (n=27) P 
Gender, n (%) 
   Male 
   Female 
 
5 (71.4) 
2 (28.6) 
 
19 (70.4) 
8 (29.6) 
 
0.956
* 
Gestational age at birth (weeks), median (min-max) 36 (30-37) 38 (25-40) 0.177
§
 
Birth weight (grams), median (min-max) 3120 (1530-4270) 2410 (705-3865) 0.357
§
 
Small for gestational age, n (%) 0 4 (14.8) 0.559
*
 
Parity, n (%) 
   Single 
   Multiple 
 
7 (100) 
0 
 
23 (85.2) 
4 (14.8) 
 
0.559
*
 
Prenatal diagnosis, n (%) 6 (85.7) 0 0.999
*
 
Gestational age at diagnosis (weeks), mean (±SD) 29.2 (±4.3) - - 
In utero intervention, n (%) 3 (42.9) 0 0.006
*
 
Delivery, n (%) 
   Vaginal 
   C-section 
 
1 (14.3) 
6 (85.7) 
 
11 (40.7) 
16 (59.3) 
 
0.378
*
 
Apgar score, n (%) 
   1
st
 minute < 7  
   5
th
 minute < 7 
 
5 (71.4) 
5 (71.4) 
 
9 (33.3) 
3 (11.1) 
 
0.097
* 
0.004
*
 
Endotracheal intubation at birth, n (%) 4 (66.7) 13 (54.2) 0.672
*
 
Thoracocentesis in delivery room, n (%) 2 (28.6) 0 0.037
*
 
Laterality, n (%) 
   Unilateral 
       Right 
       Left 
   Bilateral 
 
0 
0 
0 
7 (100) 
 
18 (66.7) 
7 (38.9) 
11 (61.1) 
9 (33.3) 
 
0.002
* 
0.999
* 
 
0.002
* 
Volume, n (%) 
   Small 
   Moderate 
   Large 
 
2 (28.6) 
4 (57.1) 
1 (14.3) 
 
5 (18.5) 
17 (63.0) 
5 (18.5) 
 
0.841
*
 
Respiratory distress, n (%) 5 (71.4) 21 (77.8) 0.999
*
 
Other associated effusions, n (%) 
   Ascites 
   Pericardial 
   Subcutaneous edema 
5 (71.4) 
5 (100) 
3 (60.0) 
5 (100) 
4 (14.8) 
4 (100) 
1 (25.0) 
3 (75.0) 
0.014
* 
0.007
* 
0.021
* 
0.004
*
 
Associated congenital malformation, n (%) 
   Heart disease 
   Diaphragmatic hernia 
   Esophageal atresia 
   Others 
 
0 
0 
0 
0 
 
13 (48.1) 
6 (22.2) 
6 (22.2) 
1 (3.7) 
 
 
<0.0001
* 
Chromosomopathy, n (%) 0 3 (14.3) 0.999
*
 
Dysmorphic syndrome, n (%) 0 2 (7.4) 0.999
*
 
Neonatal morbidity, n (%) 
   Hyaline membrane disease 
   Brochopulmonary dysplasia 
   Patent ductus arteriosus 
       Surgical closure 
   Necrotizing enterocolitis ≥ grade 2 
   Intraventricular hemorrhage ≥ grade 3 
   Leukomalacia periventricular 
   Retinopathy of prematurity ≥ grade 2 
   Sepsis 
   Pneumonia 
 
1 (16.7) 
0 
1 (14.3) 
0 
0 
0 
0 
0 
2 (28.6) 
0 
 
6 (22.2) 
3 (11.1) 
13 (48.1) 
4 (50) 
1 (3.7) 
1 (50) 
3 (11.5) 
2 (50.0) 
17 (63) 
3 (11.5) 
 
0.999
* 
0.589
* 
0.198
* 
0.999
* 
0.999
* 
0.999
* 
0.607
* 
0.999
* 
0.199
* 
0.607
*
 
Previous thoracic surgery, n (%) 
   Day of diagnosis after surgery, median (min-max) 
0 
0 
25 (92.6) 
6 (1-63) 
<0.0001
* 
0.999
* 
Duration of pleural effusion (days), median (min-max) 9 (1-30) 13 (1-108) 0.379
§
 
Treatment, n (%) 
   Spontaneous resolution 
   Thoracocentesis 
   Chest tube 
       Duration (days), median (min-max) 
   Octreotide 
       Duration (days), median (min-max) 
   Medium-chain triglycerides  
   Albumin infusion 
   Diuretics 
   Thoracic duct ligation 
 
1 (14.3) 
5 (71.4) 
3 (42.9) 
5 (2-11) 
2 (28.6) 
3 (2-4) 
4 (57.1) 
2 (28.6) 
0 
0 
 
2 (7.4) 
5 (18.5) 
21 (77.8) 
10 (1-54) 
10 (37.0) 
21 (1-40) 
12 (44.4) 
4 (14.8) 
14 (51.9) 
2 (7.4) 
 
0.999
* 
0.014
* 
0.157
* 
0.234
§
 
0.999
*
 
0.121
§
 
0.681
*
 
0.580
* 
0.026
* 
0.999
* 
Mechanical ventilation, n (%) 
   Mechanical ventilation (days), median (min-max) 
5 (71.4) 
7 (1-19) 
26 (96.3) 
21 (4-96) 
0.039
¥ 
0.013
§
 
Oxygen therapy, n (%) 
   Oxygen therapy (days), median (min-max) 
5 (71.4) 
7 (1-33) 
26 (96.3) 
19 (1-167) 
0.039
¥ 
0.071
§
 
Start of enteral feeding (days), median (min-max) 0 30 (14-106) 0.999
§
 
Parenteral feeding, n (%) 
   Parenteral feeding (days), median (min-max) 
3 (42.9) 
12 (11-38) 
26 (96.3) 
21 (1-119) 
0.003
* 
0.315
§ 
NICU stay (days), median (min-max) 9 (1-48) 42 (6-167) 0.004
§
 
Deceased, n (%) 3 (42.9) 8 (29.6) 0.656
* 
*
 Fisher’s exact test, §Mann-Whitney U test, ¥Chi-square test 
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